Test Directory
Factor XII (12) Inhibitor Titer
Justification
Acquired factor deficiencies may occur due to the development of factor-specific inhibitory antibodies. These antibodies may also develop against factor replacement products in patients with a congenital deficiency. This test may be used to detect and quantitate inhibitory antibodies against Factor XII.
STAT: < 24 hours (7 days a week)
Bethesda, Clot-based
Draw Tube: Blue Top
Sample Type: Citrated Plasma
Specimen Requirements
Sample Type | Volume Required | Minimum Volume | Stability | |
---|---|---|---|---|
PREFERRED | Citrated Plasma | Two aliquots, 1mL each | Two aliquots, 0.5mL each | Frozen (-20C): 2 weeks Frozen (-80C): 6 months |
ALTERNATIVE | - | - | - | - |
REJECTION CRITERIA | Thawed in transit, refrozen or clotted sample |
SPECIAL INSTRUCTIONS | - |
General Information
METHODOLOGY | Bethesda, Clot-based |
STAT TAT | < 24 hours (7 days a week) |
STAT TAT Performance | > 90% of results released in 24 hours 7 days a week |
ROUTINE TAT | < 3 days (M-F) |
ALTERNATIVE NAMES | Hageman Factor inhibitor, F12 inhibitor, FXII inhibitor |
DESCRIPTION | Bethesda titer for the quantitative determination of a specific factor inhibitor against factor XII (12). |
LIMITATIONS | - |
NORMAL RANGE | < 0.4 BU |
ASSOCIATED TESTING | - |
REFERENCES | - |
SAMPLE REPORT | Upon request |
NEW YORK STATE APPROVED | No |
Test Codes
ORDER CODE | P3417 |
CPT CODE | 85280, 85335 |
LOINC CODE | 3232-6 |